News

Find updates on the work of our researchers here, as well as news about recent advances in Alzheimer's science, funding and awareness.

David Holtzman, M.D., Receives Faculty Achievement Award

David Holtzman, M.D., member of the Cure Alzheimer’s Fund Research Consortium, will receive the 2015 Carl and Gerty Cori Faculty Achievement Award from his home institution, Washington University in St. Louis. The award goes to faculty members who “embody the ideals of individual and collaborative excellence” and “have made significant contributions to their fields,” according to Washington University Chancellor Mark S. Wrighton.

Research Consortium Recap

Every year the Cure Alzheimer’s Fund (CAF) Research Consortium members get together with the Board of Directors to discuss their respective research projects, refine their strategy, and leave with a clear mission. This year was no exception.

Featured Researcher: Alexandra Newton, Ph.D.

By the time she was 17, Alexandra Newton had lived in seven different countries and had mastered four different languages. But her family was not surprised when she chose to pursue a career in biochemistry instead of language arts.

‘Cancer Protein’ Linked to Alzheimer’s

In a significant discovery, a group of proteins long associated with cancer research has been shown to have an important link to Alzheimer’s disease.

Rudy Tanzi, Ph.D., Named One of TIME's 100 Most Influential People of 2015

Rudy Tanzi, Ph.D., chair of the Cure Alzheimer's Fund Research Consortium, was named one of TIME Magazine's '100 Most Influential People of 2015' in a list published earlier this week.

Tanzi has long been known for his pioneering work in Alzheimer's disease research, especially Alzheimer's genetics. He made an especially important contribution to the field in 2014 with his lab's "Alzheimer's in a Dish" breakthrough, a tool that will be used to enhance our understanding of the disease and accelerate drug discovery.

Cure Alzheimer’s Fund Receives 4th Consecutive 4-Star Rating on Charity Navigator

For the fourth year in a row, Cure Alzheimer’s Fund has received a 4-star rating – the highest possible – from watchdog organization Charity Navigator. Charity Navigator rates over 8,000 nonprofits on many aspects of their accountability, transparency and fiscal responsibility.

Promising New Alzheimer’s Drug Validates Anti-Amyloid Approach

As reported recently in the New York Times (Business Day, March 20, 2015, “Biogen Reports Its Alzheimer’s Drug Sharply Slows Cognitive Decline”) and other media, the pharmaceutical company Biogen has announced impressive results in a Phase I “human safety” trial of a new drug designed to treat — and possibly prevent — Alzheimer’s disease.

Massachusetts General Hospital Highlights CAF's Contributions to Research

In a recent news piece, Massachusetts General Hospital (MGH) chose to highlight Cure Alzheimer's Fund's support of research through the lab of Dr. Rudy Tanzi.

MGH praises the venture capital approach taken by CAF co-founders Jeff and Jacqui Morby, enabling researchers like Tanzi to take risks and pursue "paradigm changing" studies. And the risks have paid off: According to MGH, the scientific results brought about by CAF-funded research are "nothing short of game changing, as Mass General researchers resolve some long-unanswered questions about how Alzheimer’s disease develops."

President's 2016 Budget Includes More Funding for Alzheimer's Research

Released today, the President's Fiscal Year 2016 Budget includes several important increases for medical research. The National Institutes of Health (NIH) will receive an additional $1 billion, incuding $68 million for the National Institute on Aging. These represent roughly a 1.1% and a 3.3% increase in NIH and NIA's respective budgets.

Driving Genes to Therapies

Building on its enormously successful “Whole Genome Sequencing” Project, which identified nearly 1,000 new genetic mutations in more than 50 different genes, Cure Alzheimer's Fund has announced a new, even more ambitious multiyear, $50 million plus program titled “Genes to Therapies” (G2T). Simply put, the new project’s goal is to use the most promising recent genetic discoveries to develop drugs that would stop the disease at three separate stages: